Milano Furuta - 18 Mar 2026 Form 3 Insider Report for TAKEDA PHARMACEUTICAL CO LTD (TAK)

Role
Chief Financial Officer, Director
Signature
/s/ Max Heuer, by power of attorney, for Milano Furuta
Issuer symbol
TAK
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 06:12:16 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Furuta Milano Chief Financial Officer, Director 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO, JAPAN /s/ Max Heuer, by power of attorney, for Milano Furuta 18 Mar 2026 0002111400

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TAK Ordinary Shares 50,100 18 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TAK Tax Obligation Award 18 Mar 2026 Ordinary Shares 8,805 Direct F2
holding TAK Tax Obligation Award 18 Mar 2026 Ordinary Shares 7,453 Direct F2
holding TAK Tax Obligation Award 18 Mar 2026 Ordinary Shares 4,194 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 19,500 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest on the following schedule: June 1, 2026 (8,400 shares), June 1, 2027 (7,100 shares) and June 1, 2028 (4000 shares).
F2 Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.

Remarks:

Exhibit 24 Power of Attorney